Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005 Feb;54(2):314-5; author reply 316-6.

Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease

P Rosenstiel, J Agnholt, J Kelsen, V Medici, G H Waetzig, D Seegert, S Schreiber
Comment

Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease

P Rosenstiel et al. Gut. 2005 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intestinal CD4+ T cells were obtained from colonic biopsies from five patients with Crohn’s disease (median age 34 years (range 18–49)) with an established diagnosis of Crohn’s disease based on histopathological and endoscopic criteria. All patients had active disease at inclusion and were treated with 5-ASA (2–4 g/day, five patients), prednisone (20 mg/day, one patient), and azathioprine (150–200 mg/day, four patients). None of the patients had received anti-TNF-α treatment. Neither antigen nor feeder cells were added to the intestinal T cells cultures, which consisted of more than 97% CD3+/CD4+ T cells. (A) Infliximab, but not etanercept, activated p38α and induced apoptosis in intestinal T lymphocytes from Crohn’s disease patients. Levels of (phosphorylated) p38 mitogen activated protein kinase (MAPK) and PARP in in situ activated intestinal T lymphocytes were investigated by western blot 24 hours after stimulation with the respective TNF-α binding agent, as described previously. Data are representative of experiments performed in all patients, n = 5. (B) Signal transducer and activator of transcription 3 (STAT3) was activated in CD4+ cells in the intestinal mucosa in Crohn’s disease patients in vivo and downregulated by both infliximab and etanercept in intestinal T cells from Crohn’s disease patients in vitro. Western blot and immunofluorescence staining were performed as described previously. Filled arrowheads, cells positive for phospho-Y-STAT3 (anti-phospho-Y-STAT3, 1/100; Cell Signaling Technology) and CD4 (anti-CD4, 1/500; BD PharMingen, San Diego, California, USA); open arrowhead, CD4 immunoreactivity only (n = 5 for immunofluorescence and western blot; representative result for all experiments).
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. ten Hove T , van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002;50:206–11. - PMC - PubMed
    1. Lugering A , Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145–57. - PubMed
    1. Waetzig GH, Seegert D, Rosenstiel P, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002;168:5342–51. - PubMed
    1. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003;124:1774–85. - PubMed
    1. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–94. - PubMed

MeSH terms